title: Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.
abstract: Therapeutic antibodies are large molecule drugs that do not cross the blood-brain barrier (BBB). Therefore, drug development of therapeutic antibodies for Alzheimer's disease (AD) requires that these molecules be re-engineered to enable BBB delivery. This is possible by joining the therapeutic antibody with a transporter antibody, resulting in the engineering of a BBB-penetrating bispecific antibody (BSA). Areas covered: The manuscript covers transporter antibodies that cross the BBB via receptor-mediated transport systems on the BBB, such as the insulin receptor or transferrin receptor. Furthermore, it highlights therapeutic antibodies for AD that target the Abeta amyloid peptide, beta secretase-1, or the metabotropic glutamate receptor-1. BSAs are comprised of both the transporter antibody and the therapeutic antibody, as well as IgG constant region, which can induce immune tolerance or trigger transport via Fc receptors. Expert opinion: Multiple types of BSA molecular designs have been used to engineer BBB-penetrating BSAs, which differ in valency and spatial orientation of the transporter and therapeutic domains of the BSA. The plasma pharmacokinetics and dosing regimens of BSAs differ from that of conventional therapeutic antibodies. BBB-penetrating BSAs may be engineered in the future as new treatments of AD, as well as other neural disorders.
authors: a Brain Research Institute , University of California , Los Angeles , CA , USA.
authors: William M
authors: WM
authors: Pardridge
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism*; D053829:Amyloid Precursor Protein Secretases / Q000378:metabolism; D000818:Animals; D018033:Antibodies, Bispecific / Q000378:metabolism* / Q000627:therapeutic use; D015703:Antigens, CD / Q000378:metabolism; D016282:Aspartic Acid Endopeptidases / Q000378:metabolism; D001692:Biological Transport / Q000502:physiology; D001698:Biomedical Engineering / Q000379:methods*; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D010455:Peptides / Q000627:therapeutic use; D011972:Receptor, Insulin / Q000378:metabolism; D011990:Receptors, Transferrin / Q000378:metabolism
chemical_list: D018033:Antibodies, Bispecific; D015703:Antigens, CD; C068126:CD71 antigen; D010455:Peptides; D011990:Receptors, Transferrin; C435941:INSR protein, human; D011972:Receptor, Insulin; D053829:Amyloid Precursor Protein Secretases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human
keywords: Alzheimer’s disease; Blood-brain barrier; CSF; bispecific antibody; brain drug delivery